Profusa (NASDAQ:PFSA) Releases Earnings Results

Profusa (NASDAQ:PFSA) announced its quarterly earnings data on Wednesday. The company reported ($151.80) earnings per share (EPS) for the quarter, FiscalAI reports.

Profusa Price Performance

Shares of Profusa stock opened at $7.57 on Friday. The stock has a market cap of $378,500.00, a price-to-earnings ratio of -0.00 and a beta of 0.52. The firm’s 50-day moving average is $9.82 and its two-hundred day moving average is $75.11. Profusa has a 1 year low of $3.22 and a 1 year high of $5,190.00.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Profusa from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Insiders Place Their Bets

In other news, major shareholder Financial Lp Hrt sold 10,602 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $3.56, for a total value of $37,743.12. Following the sale, the insider directly owned 18,549 shares in the company, valued at approximately $66,034.44. This trade represents a 36.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders bought a total of 4,308 shares of company stock worth $16,594 over the last 90 days. 0.76% of the stock is owned by company insiders.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.